New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
08:36 EDTRIGLRigel still poised to report good fostamatinib results, says Stifel Nicolaus
After Rigel Pharmaceuticals reported that its fostamatinib drug for rheumatoid arthritis.had failed to demonstrate non-inferiority versus a competing drug, Stifel reports that the results don't alter its forecast for fostamatinib's Phae III trials. The firm thinks the decline in Rigel's stock following the results were overdone and it maintains a Buy rating.
News For RIGL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:32 EDTRIGLRigel Pharmaceuticals announces retirement of Chairman and CEO James Gower
Rigel Pharmaceuticals announced James Gower is retiring from the board and from his positions as Chairman and CEO, and Raul Rodriguez, most recently serving as the company's President and COO, will assume the position of chief executive officer and join the board. Gary Lyons, a member of Rigel's board since 2005, will become chairman. Gower is expected to remain an employee until the end of the year and, thereafter will be a consultant to the company providing advice on strategy, business development and other matters.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use